Moderate depressive disorder
Conditions
Interventions
Drug -rTMS group:Drug treatment with the same drug group.The left DLPFC gave 110%rMT stimulation the sequence parameter was 10Hz continuous stimulation for 4 seconds at 26 seconds interval a total of
Drug group:According to the recommendation of the 2020 edition of the Guidelines for the Diagnosis and Treatment of Mental Disorders all groups were given Escitalopram oxalate with 5mg/ day as the sta
Drug - acupuncture group:Drug treatment with the same drug group. Acupuncture Jing moxibustion and ear acupuncture were given.
Sponsors
Guangdong Provincial Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1) Compliance with the International Classification of Diseases 10th Edition (International Classification of Diseases 10th Edition ICD-10) "moderate depressive episode" standard and "Yu disease" in the Chinese medicine industry standard of the People's Republic of China (ZY/T001.1-94); 2) Hamilton Depression Scale 17 (HAMD-17) score > 17 and =24 points; 3) Age 18-45 years old right-handed gender is not limited; 4) Able to understand and cooperate with treatment and testing arrangements without communication and cognitive dysfunction; 5) Have not received transcranial magnetic stimulation or transcranial direct current stimulation in the past 3 months; 6) Sign informed consent and participate in this study voluntarily.
Exclusion criteria
Exclusion criteria: 1) Those who have been assessed by a specialist as having suicidal tendencies or behaviors; 2) have been previously diagnosed with major depressive disorder bipolar disorder schizophrenia or other major mental disorder; 3) Severe anxiety Hamilton Anxiety Scale (HAMA) score >23 points; 4) Patients with liver and kidney dysfunction tumor or circulatory digestive endocrine respiratory and other serious basic diseases; 5) History of seizures or family history organic brain diseases and serious physical diseases; 6) Pregnant pregnant or lactating women; 7) Those who have been taking antidepressants within 6 weeks (including 6 weeks) or have received transcranial magnetic stimulation or transcranial direct current stimulation in the last 3 months or are participating in other clinical trials; 8) Patients with metal implants such as titanium mesh steel plate stent pacemaker and other transcranial magnetic stimulation contraindications; 9) Alcohol or drug abusers; 10) Individuals who are allergic to alcohol adhesive tape have skin damage at the treatment site have coagulation dysfunction or have severe scar constitution; 11) Diseases of the digestive system (such as cirrhosis inflammatory bowel disease etc.) endocrine and metabolic diseases (such as diabetes obesity or fatty liver); Use of antibiotics probiotics prebiotics or symbionins within 6 months prior to collection of stool samples; Drug or alcohol abuse; Known active bacterial fungal or viral infections; And obvious dietary preferences (e.g. vegetarian).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Depression ScaleHAMD-17; | — |
Secondary
| Measure | Time frame |
|---|---|
| Concise compliance rating scale;Emotional regulation questionnaireERQ-R;Thought control questionnaireTCQ-R;Mood disorders questionnaireMDQ;ElectroencephalogramEEG;Insomnia severity index scaleISI;Pittsburgh Sleep Quality Index ScalePSQI;Suicidal attitudes questionnaire;Multidimensional evaluation of interoceptive perception;Stanford Treatment Expectation Scale;Baker depression scaleBDI;Eisenberg antidepressant Adverse Reaction Scale;Hamilton Anxiety Scale HAMA-14;Generalized Anxiety Disorder ScaleGAD-7; | — |
Countries
China
Contacts
Public ContactWu Qian
Guangdong Provincial Hospital of Traditional Chinese Medicine
Outcome results
None listed